摘要
背景:肾病是糖尿病的一种使人虚弱的并发症,与肾功能衰竭风险增加有关,导致患者的生活质量较差,最终导致死亡。早期干预对于增进肾病患者的健康至关重要。不幸的是,它不是肾损伤的早期标志物,白蛋白尿是糖尿病和高血压患者肾功能衰退的一个众所周知的预测指标。 目的:评估新的和精确的标记物对于预测肾病的早期发作和进展是必要的。即使在出现临床症状(无微量白蛋白尿)之前,找到可预测肾脏损伤的早期标记也很重要。 结果:使用替代标志物如血清肌酸酐预防和治疗肾脏疾病未被证明是已被证明可降低发病率或死亡率的干预措施的更好指标。许多研究已经阐明了肾损伤标记物的重要性。本文介绍了尿标记物如nephrin,Cystatin C,Monocyte chemoattractant protein(MCP-1),中性粒细胞明胶酶相关脂质运载蛋白(NGAL),肾损伤分子-1(KIM-1)和巢蛋白的意义,早期肾功能不全。 结论:虽然药物治疗取得了显着进展,但与肾病有关的发病率和死亡率依然高居不下。除了血清标记物之外,尿标记物可以更好地预测糖尿病患者对肾脏的损伤进展。
关键词: 糖尿病,炎症,肾脏疾病,尿路标记,肾病,肾功能衰竭。
图形摘要
Current Drug Targets
Title:Early Urinary Markers for Diabetic and Other Kidney Diseases
Volume: 19 Issue: 7
关键词: 糖尿病,炎症,肾脏疾病,尿路标记,肾病,肾功能衰竭。
摘要: Background: Nephropathy is a debilitating complication of diabetes associated with increased risk for renal failure, leading to poor quality of life of the affected patients and eventually to mortality. Early intervention is crucial to enhance the well-being of the patients with nephropathy. Albuminuria is a well-known predictor of weak renal outcomes in patients with diabetes and hypertension, unfortunately, it is not an early marker for kidney injury.
Objective: Assessment of new and precise markers is necessary to predict the early onset and progression of nephropathy. It is important to find early markers which could predict kidney injury even before the clinical signs (no microalbuminuria) appear.
Results: Prevention and therapy for kidney diseases using surrogate markers such as serum creatinine have not proven to be better indicators for interventions that have been shown to decrease morbidity or mortality. A number of studies have elucidated the importance of kidney injury markers. This article describes the significance of urinary markers such as nephrin, Cystatin C, Monocyte chemoattractant protein (MCP-1), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM- 1) and nestin, which are associated with early renal dysfunction.
Conclusion: Although significant advances have been made in medical therapy, the degree of morbidity and mortality associated with kidney diseases remain despondently high. Besides the serum markers, urinary markers may provide a better prediction of progression of the damage to the kidneys in diabetic patients.
Export Options
About this article
Cite this article as:
Early Urinary Markers for Diabetic and Other Kidney Diseases, Current Drug Targets 2018; 19 (7) . https://dx.doi.org/10.2174/1389450119666180319124639
DOI https://dx.doi.org/10.2174/1389450119666180319124639 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Compounds that Combine Aldose Reductase Inhibitory Activity and Ability to Prevent the Glycation (Glucation and/or Fructation) of Proteins as Putative Pharmacotherapeutic Agents
Drug Design Reviews - Online (Discontinued) Editorial [Hot Topic: Benefits, Problems and Alternatives to COX-2 Inhibition (Guest Editor: Angel Lanas)]
Current Topics in Medicinal Chemistry The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade
Current Clinical Pharmacology Translational Research in Oncology: The Need of Additional In Vitro Preclinical Testing Methods for New Drugs
Current Pharmaceutical Design Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Current Drug Targets High-dose Cholecalciferol Supplementation Reducing Morning Blood Pressure in Normotensive DM1 Patients
Current Diabetes Reviews The Genetics and Genomics of Systemic Sclerosis: An Update and Review
Current Rheumatology Reviews Therapeutic Utilisations of Vasopressin and Oxytocin in Mood Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) A Review of the Therapeutic Benefits of Moringa oleifera in Controlling High Blood Pressure (Hypertension)
Current Traditional Medicine Metastatic Gastro-intestinal Neuroendocrine Tumors: A Case Report of Real Life Management Challenges and Success
Current Cancer Therapy Reviews Oxidative Stress in Diabetic Nephropathy
Current Medicinal Chemistry Changes in the Density of Corneal Endothelial Cells in Elderly Diabetic Patients After Combined Phacovitrectomy and Ex-PRESS Glaucoma Implants
Current Pharmaceutical Biotechnology Fetal Protein Restriction, Taurine and Islet Plasticity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Is Glyburide Safe in Pregnancy?
Current Pharmaceutical Biotechnology Aquaretic Agents: Whats Beyond the Treatment of Hyponatremia?
Current Pharmaceutical Design Vasopressin and Related Peptides; Potential Value in Diagnosis, Prognosis and Treatment of Clinical Disorders
Current Drug Metabolism Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure
Current Pharmaceutical Design Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based “Triple Therapy” Experience in Southern Italy
Reviews on Recent Clinical Trials FDG-PET Scanning Shows Distributed Changes in Cortical Activity Associated with Visual Hallucinations in Eye Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Therapeutic Alternatives and New Perspectives in Glioblastoma Multiforme
Current Medicinal Chemistry